Human cytomegalovirus (HCMV) encodes several highly polymorphic envelope glycoproteins; however, the biological relevance of this polymorphism is unclear. Glycoprotein N (gN) is one member of this polymorphic protein family. Four major gN genotypes (gN1-4) have been identified. We have tested the hypothesis that the gN polymorphism represents a mechanism to evade a neutralizing antiviral antibody response. Four recombinant viruses that differed only in the expression of the gN genotype were constructed on the genetic background of HCMV strain AD169. Exchange of gN genotypes had a minor detectable influence on virus replication, gN expression and gN-gM complex formation. Randomly selected human sera were analysed for neutralizing activity against the recombinant viruses. Of these, 70 % showed no difference in neutralizing titre between the viruses, whereas 30 % showed strain-specific neutralization. Differences in 50 % neutralization titre reached .8-fold. Viruses expressing the gN4 genotype were neutralized significantly better than those expressing the other gN genotypes. Strain specificity, or lack thereof, could not be attributed to the presence or absence of anti-gN antibodies, as all sera contained antibodies reacting with gN (as determined by ELISA). Thus, polymorphism of gN could contribute to evasion of an efficient neutralizing-antibody response and facilitate reinfection in previously seropositive individuals.
INTRODUCTION
Human cytomegalovirus (HCMV) is a significant cause of morbidity and mortality in immunocompromised individuals, such as transplant recipients, AIDS patients and newborns (Britt, 2006) . A puzzling aspect of HCMV biology is the fact that a large number of genetically distinct HCMV strains circulate in the population (Chandler & McDougall, 1986; Chou, 1990; Rasmussen et al., 2002 Rasmussen et al., , 2003 Murphy et al., 2003; Pignatelli et al., 2003) . The presence of more than one strain has been observed in immunocompetent persons, indicating the possibility of simultaneous coinfection with multiple different virus strains or reinfection in the presence of a functional immune response (Chandler et al., 1987; Bale et al., 1996; Schoppel et al., 1997; Boppana et al., 2001 ). In immunocompromised patients, reinfection may represent a clinically important problem, as a de novo adaptive immune response against the reinfecting strain is impaired. Clinical studies in transplant patients have supported the importance of HCMV reinfection in these patients (Grundy et al., 1988; Coaquette et al., 2004; Ishibashi et al., 2007) . Moreover, in women who are seropositive for HCMV, reinfection with a different strain can lead to intrauterine transmission and symptomatic congenital infection (Boppana et al., 2001) . In the closely related murine cytomegalovirus (MCMV), simultaneous or sequential infection with different virus strains results in mixed infections in immunocompetent mice (Farroway et al., 2005; Gorman et al., 2006) . Thus, reinfection with different strains of cytomegalovirus is frequent in both immunocompetent and immunocompromised hosts.
The defect in immune effector function(s) that leads to reinfection has not been defined. One likely possibility, based on the precedence in other viruses such as influenza viruses, may be related to evasion of virus-neutralizing antibodies secondary to sequence variation in envelope glycoproteins. Consistent with this possibility has been the finding of antigenic diversity among HCMV isolates that precludes complete neutralization by a given polyclonal serum or monoclonal antibody, a finding that is wellestablished and documented in numerous studies (Waner & Weller, 1978; Baboonian et al., 1989; Simpson et al., 1993; Klein et al., 1999) . Of special interest in this respect are virus envelope glycoproteins, as they represent the targets for neutralizing antibodies. HCMV is a complex virus that contains .20 envelope proteins (Varnum et al., 2004; Patrone et al., 2005; Wang & Shenk, 2005; Adler et al., 2006) . Glycoproteins B (gB), gH and gN have been identified as major antigens that are capable of inducing neutralizing antibodies during natural infection (Britt et al., 1990; Urban et al., 1996; Shimamura et al., 2006) . Primary amino acid sequences for gB and gH are highly conserved between different HCMV strains, with similarity of .95 %. Nevertheless, strain-specific epitopes have been identified on both proteins (Meyer et al., 1992; Urban et al., 1992) . The contribution of these minor variations to neutralization resistance against polyspecific human sera has not been analysed. In contrast to gB and gH, gN is an extremely polymorphic protein (Pignatelli et al., 2003) . Four major genotypes have been identified. Differences between the genotypes are located exclusively within the extraviral domain, reaching amino acid differences of up to 50 % between genotypes (Pignatelli et al., 2003) .
A potentially important consequence of gN polymorphism is evasion of neutralizing antibodies. Previous studies have provided evidence for a role of virus-neutralizing antibodies in the outcome of HCMV infections in both immunocompetent and immunocompromised individuals, and results from our laboratories have demonstrated that the gM-gN complex is a dominant target for HCMV-neutralizing antibodies (Adler et al., 1995; Schoppel et al., 1998; Shimamura et al., 2006) . In the latter study, virusneutralizing antibodies were shown to be directed at the gN component of the gM-gN complex. Pignatelli et al. (2003) suggested that variation of the gN amino acid sequence could be secondary to immune pressure and selection. Together, these studies have raised the possibility that gN polymorphism could contribute to the phenomenon of reinfection with this virus by its role in the strain-specific recognition of HCMV by neutralizing antibodies. To begin to understand the host-and virus-determined factors that lead to reinfection with HCMV of previously immune individuals, we have tested the hypothesis that gN polymorphism contributes to the phenomenon of HCMV strainspecific neutralization by human antibodies found in the sera of HCMV-seropositive individuals. Our results revealed that approximately 30 % of sera from HCMV-seropositive individuals exhibited significant differences in neutralization capacity against four recombinant viruses that differed only in the expression of the gN genotype, constructed on the genetic background of HCMV AD169. This indicates that gN polymorphism might contribute to evasion of the antiviral humoral immune response and predispose individuals to infection with an unrelated strain of HCMV.
METHODS
Cells and viruses. Human kidney cell line 293T and human lung fibroblasts (MRC5) were maintained in Dulbecco's modified Eagle medium with 10 % fetal calf serum, glutamine (100 mg l
21
) and gentamicin (350 mg l
). Virions were isolated by glycerol-tartrate gradient centrifugation as described by Talbot & Almeida (1977) . For growth curves, fibroblasts were infected at an m.o.i. of 0.01 as determined by immunostaining of immediate-early protein 1 (IE-1). After adsorption of virus for 4 h, the inoculum was removed and replaced by fresh medium. Supernatants from infected cultures were harvested at the indicated time points and stored at 280 uC until use. Virus titres in the supernatants were determined by an indirect immunofluorescence assay (Andreoni et al., 1989) . Neutralization assays using extracellular virions were performed as described previously (Klein et al., 1999) . The HCMV strains were isolated from congenital infection (gN1) and bone-marrow transplant (gN3, gN4) patients and used between passages 5 and 10. gN2 was a kind gift of P. Dal Monte, S. Orsola-Malpighi General Hospital, University of Bologna, Bologna, Italy.
Antibodies and sera. The monoclonal antibodies (mAbs) used in this study have been described previously: IE1-specific mAb p63-27 (Andreoni et al., 1989) , gM-specific mAb IMP 91-3/1 (Mach et al., 2000) , gB-specific murine mAb 27-287 (Schoppel et al., 1996) and human mAb C23 (Meyer et al., 1990) , gp65(gN)-specific mAb 14-16A (Britt & Auger, 1985) and gH-specific mAb 14-4b (Simpson et al., 1993) . Secondary antibodies were from Dianova and DAKO. HCMV-positive and -negative human sera were obtained in blinded fashion from discarded patient samples submitted to the diagnostic laboratory of the Institute for Virology, Friedrich-Alexander Universität, and heat-inactivated for 30 min at 56 uC.
Plasmids. Plasmids for the expression of gM (pcIMP) and gN (pcUL73flag) of HCMV strain AD169 have been described previously (Mach et al., 2000) . To generate expression plasmids for the individual gN genotypes, DNA from HCMV isolates was amplified by PCR using primers 73up5 (59-ACCGAATTCATGGAGTGGAA-CACACTAG) and 73-3 (59-ACCCAAGCTTATAGCCTTTGGT-GGTGGTTG) and inserted into the vector pcDNA3.1myc/his (Invitrogen). To generate fragments for recombination in Escherichia coli, we used the previously described plasmid pCPo-Delta73 (Mach et al., 2005) . The coding sequences corresponding to the individual gN genotypes were inserted into pCPo-Delta73 between open reading frame (ORF) UL72 and the kanamycin-resistance gene (kan). The corresponding plasmids were designated pCPo-UL73-1 to -4.
Bacterial artificial chromosome (BAC) mutagenesis and reconstitution of BAC-derived virus. From plasmids pCPo-UL73-1, -2, -3 and -4, recombination cassettes comprising 40 bp of ORF UL72, ORF UL73 and kan flanked by two FLP recombinase target sites and 146 bp of ORF UL74 were obtained by PCR using the primers UL72up5 (59-CCAGTTGAGAGTCGATTC) and UL73Rec3 (59-GGGACTATCTAGACTCGCTG). RecE/T-mediated recombination with HB5-BAC (Borst et al., 1999; Datsenko & Wanner, 2000) and reconstitution of BAC-derived infectious virus was done as described previously (Mach et al., 2005) .
Cell-based ELISA. 293T cells were transfected with plasmids encoding gM-gN by using the calcium phosphate precipitation method. After 48 h cells were harvested, washed three times with PBS and sonicated three times for 5 s in a buffer containing 0.2 mM EDTA and 1 mM sodium carbonate, pH 7. For preparation of gMgN antigens, 293T cells were transfected with plasmids encoding gM, the respective gN subtypes and pEGFP-N2 (Clontech). Forty-eight hours later, cells were harvested and subjected to cell sorting for enhanced green fluorescent protein-positive cells by using a MoFlo Journal of General Virology 90 Downloaded from www.microbiologyresearch.org by IP: 54.70.40.11
On: Sat, 27 Jul 2019 00:43:03 cell sorter (Cytomation). Sorted cells were sonicated three times for 5 s. Differential centrifugation at 1500 r.p.m. for 10 min and subsequent centrifugation of the supernatant at 15 000 r.p.m. for 30 min yielded a pellet containing a membrane-enriched cell fraction (referred to as cell lysates). The pellets were resuspended in 0.2 mM EDTA/1 mM sodium hydrogen carbonate buffer. Ninety-six-well plates were coated with either 1 mg gM-gN or 0.5 mg gM cell lysates overnight at 4 uC. Wells were rinsed three times with washing buffer (PBS, 0.05 % Tween 20) and blocked with blocking buffer (PBS, 5 % fetal calf serum) at 37 uC for 2 h. Blocking solution was removed and mAb or human serum diluted 1 : 100 was applied for 2 h at 37 uC. Wells were washed three times with washing buffer and incubated with peroxidase-linked anti-human IgG at 37 uC for 1 h. After three washing steps, 100 ml TMB substrate (Medac) was added. Reactions were stopped with 100 ml phosphoric acid. To control for gM-specific antibody titres in human sera, the mAb IMP91/3-1 (directed against gM) was used to normalize for amount of gM in wells containing either gM or gM-gN. To determine anti-gB antibody titres, 50 ng purified recombinant gB per well (Sanofi Pasteur) was used as antigen.
Immunization of mice. In groups of 10, C57/Bl6 mice were immunized with 5 mg each of the individual RVHB5-gN viruses three times intraperitoneally at intervals of 6 weeks. Two weeks after the last immunization, animals were killed and serum was collected.
RESULTS

Construction and characterization of recombinant gN subtype viruses
We first constructed recombinant HCMVs that differed only in the coding sequence of gN. HCMV gN protein sequences have been grouped into four major subtypes, gN1-4, with gN3 being further divided into two subgroups (gN3a and b) and gN4 into three subgroups (gN4a, b and c) (Pignatelli et al., 2003) . The gN sequences that we have used to construct recombinant viruses for this study were derived from low-passage clinical HCMV isolates and show closest similarity to gN1, gN2, gN3a and gN4a, respectively (Fig. 1a) . gN subtype recombinant viruses were originally constructed as BACs in the genetic background of HCMV strain AD169 by using BAC HB-5 (Borst et al., 1999) . The strategy for construction was identical to that used in our previous work (Mach et al., 2005) . Replicating virus was recovered for all four gN subtype viruses. PCR amplification and nucleotide-sequence determination of the genomic region encoding UL73 and flanking UL72/UL74 Replication kinetics of gN-recombinant viruses. Fibroblasts were infected with identical infectious doses of the different viruses at day 0. At the indicated days post-infection, supernatants from the infected cultures were harvested and virus titre was determined. h, RVAD169; e, RVAD-gN1; g, RVAD-gN2; #, RVAD-gN3; ¾, RVAD-gN4. (c) Analysis of the gM-gN complex in extracellular virus particles. Lysates from gradient-purified extracellular virions were subjected to Western blot analysis under non-reducing conditions. The blot was first stained for gB by using antibody 27-287 to adjust for the amount of envelope components, then stripped and redeveloped with antibody 14-16A (anti-gN). (d) Neutralization capacity of the gB-specific human mAb C23 towards the gN-recombinant viruses. X, RVAD-gN1; &, RVAD-gN2; m, RVAD-gN3; ¾, RVAD-gN4.
verified that the recombinant viruses contained the prototypical UL73/UL74 gene arrangement (data not shown).
To determine whether exchange of the gN gene had an impact on virus replication in permissive human fibroblasts, we performed multi-step replication curves. Fibroblasts were infected with parental virus RVAD169 [RV-HB5 as established by Borst et al. (1999) ] and the four gN recombinant viruses, and titre of infectious virus in the tissue-culture supernatant was determined between days 1 and 16 after infection. Although there were differences in the level of replication between the recombinant viruses and the parental RVAD169 virus, all four gN subtype viruses replicated to similar final titres (Fig. 1b) . Furthermore, entry of all four gN subtype viruses was similar, as measured by immunostaining of IE-1 between 1 and 5 h after infection (data not shown). This result suggested that differences in gN expression did not alter the capacity of the recombinant gN viruses to attach, penetrate and enter permissive fibroblasts. The presence and relative abundance of the gM-gN complex in purified extracellular virions were next analysed by Western blotting under nonreducing conditions. The number of virions that was used for the analysis was normalized by using a murine mAb specific for gB. As can be seen in Fig. 1(c) , the relative ratio of the gM-gN complex to gB was similar in all four recombinant viruses, suggesting that there was no preferential incorporation of specific gN genotypes into extracellular particles. In the case of the gN4 subtype virus, a slight difference in migration and band appearance of the gM-gN complex was noted, indicating the likelihood of more heterogeneous post-translational modifications of this gN subtype compared with the remaining three gN subtypes. Finally, we tested the recombinant viruses in an in vitro neutralization assay using mAbs specific for gB and gH. Similar 50 % neutralization titres were obtained for the different gN subtype viruses; data for the anti-gB mAb are shown in Fig. 1(d) . Taken together, these results indicated that the four gN subtype viruses showed little difference with respect to gM-gN complex formation, incorporation of the complex into the virion and susceptibility to in vitro neutralization by antibodies directed at abundant virus envelope glycoprotein.
Neutralization of gN subtype viruses by human sera
To test the neutralizing capacity of human sera against the four gN-recombinant viruses, we performed additional in vitro neutralization assays. Twenty sera from HCMVseropositive donors, chosen randomly from our diagnostic department without prior knowledge of clinical diagnosis, and two sera from HCMV-seronegative donors were analysed. Within the panel of sera from HCMV-seropositive donors, two different patterns of neutralizing activity were evident. The majority of sera (n514) neutralized the four gN subtype viruses equally well, as exemplified by the titration curve of a representative serum shown in Fig. 2(a) . The 50 % neutralization titre of this serum against the different gN-recombinant viruses was within a single serum dilution. Table 1 shows a summary of this group of sera with respect to neutralization titre. In contrast to this first group of sera, the remaining six sera (30 %) showed clear differences in the 50 % neutralization titre between the four gN subtype viruses. An example is shown in Fig. 2(b) and the summary of this group of sera in Table 1 . Sera that showed differences in 50 % neutralization titre exceeding three dilutions of the serum between at least two gNrecombinant viruses were classified as strain-specific, as inter-assay variation in general was within one dilution (data not shown). In the serum panel that showed a strainspecific reaction, differences in 50 % neutralization titre between the gN subtypes ranged from 3.9-to 8.1-fold. Importantly, strain-specific neutralization was not associated with low or high neutralization capacity of the respective serum (compare sera Pro and 210 in Table 1 ). However, overall, this group of sera generally neutralized gN4 subtype viruses more potently than viruses containing the other gN subtypes. When calculated over the entire sample, gN4 viruses were neutralized significantly better than the other three recombinant gN-congenic viruses, indicating that optimal neutralization of strains was not distributed randomly between the gN subtype viruses, but rather reflected the prevalence of the gN subtypes within the population (Table 1) . Together, these data demonstrated that up to 30 % of HCMV-immune individuals have circulating antibodies that preferentially neutralize only a subset of the known gN genotypes.
Because the neutralization titre reflects the sum of individual antibody specificities, the relative concentration of antibodies directed against antigens other than gN could therefore also determine whether a given serum neutralizes virus in a strain-specific or strain-common manner. HCMV encodes a number of different envelope proteins that induce neutralizing antibodies during natural infection; thus, the contribution of strain-specific responses of non-gN-specific virus-neutralizing antibodies cannot be determined, as the complete spectrum of virus antigens that are targeted by virus-neutralizing antibodies is unknown. However, as a surrogate marker, antibody titres against gB can be used, as it has been shown that gB represents an immunodominant virus antigen and that anti-gB binding antibody titres and neutralizing titres correlate (Marshall et al., 1992 ). Thus, we tested the serum panel for anti-gB antibody titre in an ELISA, using purified recombinant gB as the antigen. As shown in Fig. 3 , there was no correlation between titre of anti-gB antibody and strain-specific neutralization.
Recognition of the gM-gN complex by human sera in ELISA Identification of individuals at risk for reinfection with an antigenically different HCMV strain might represent Antibodies against gN of HCMV important information for the clinical management of individuals, including transplant recipients and pregnant women at risk for reinfection with strains of HCMV that differed in gN genotype. A gN-based ELISA could constitute a rapid method to identify sera containing strain-specific gN-related neutralizing antibodies. The antigen used in such an assay requires the presence of both gN and gM, as gN is not modified or folded correctly in the absence of gM and thus does not represent a suitable antigen (Mach et al., 2000) . gM, on the other hand, can adopt a conformation in the absence of gN that can bind antibodies, and its antibodybinding capacity is not influenced by coexpression of gN (Lehner et al., 1989; M. Mach, unpublished results) . Because gM is also the target of HCMV antibodies, any signal from an antibody-binding assay employing the gM-gN complex must also control for the antibody reactivity of gM (Mach et al., 2000) . Using cell lysates from transiently transfected cells, we measured antibody titres for gM and gM-gN and used the difference in gM and gM-gN binding indices to determine the gN-specific antibody titre.
Among the two serum panels that were classified as straincommon or strain-specific with regard to neutralization, we found no correlation between gN-specific antibody titre and neutralization capacity, i.e. sera that had the highest ELISA antibody titres against one gN subtype did not show a corresponding neutralizing activity against the virus carrying the same gN subtype (Table 2) . A good example is serum 210, which contained a comparable ELISA antibody titre against the gN3 and gN4 subtypes, whereas the neutralizing titre against the corresponding viruses differed greatly. On the other hand, serum 210 had very low ELISA titres against the gN2 protein, but was capable of neutralizing the corresponding virus better than the gN1-and gN3-expressing viruses.
When calculated over the entire serum panel, antibody titres against the gN2 subtype were found to be significantly lower than against the other gN subtypes (Table 2) . However, there were also sera that exhibited the strongest signal with gN2 (e.g. serum Kob), indicating that the reduced recognition of gN2 was not secondary to the antigen preparation. Interestingly, within the serum panel that was associated with strain-common neutralization, three of 14 (22 %) sera had lower ELISA antibody titres against gN2 than against the other three gN subtypes, whereas within the subgroup of sera showing strainspecific neutralizing activity, five of six (83 %) sera had a lower anti-gN2 ELISA antibody titre compared with the other gN subtypes (Table 2) . Thus, although the sera showed clear evidence for gN subtype-specific recognition, there was no correlation between recognition of a given gN subtype in ELISA and the corresponding strain-specific neutralization. Moreover, there was also no overall Fig. 3 . Anti-gB antibody titre and strain-specific neutralization do not correlate. Strain-common and strain-specific sera were tested in an ELISA using purified recombinant gB as the antigen and correlated with the maximal neutralization difference between the gN subtype viruses. r, Spearman's rank correlation coefficient. 
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correlation between gN antibody titre (as determined by ELISA) and neutralizing capacity (Fig. 4) .
Analysis of murine sera following immunization with gN subtype viruses
The immune response against multiple HCMV strains could obscure the true extent of strain-specific antibody response against a single virus isolate. To assay the extent of strain-specific antibodies that are induced after infection with a single HCMV gN genotype, we used immunization of mice. Groups of 10 mice were immunized with purified extracellular virions harbouring the individual gN genotypes. Sera from each group were pooled and tested in neutralization assays. No significant difference was observed between the gN subtype viruses (Table 3) . In ELISA, the murine sera also showed no difference between the gN subtypes, but provided evidence that gN-specific, but not gN subtype-specific, antibodies were induced by the immunization (data not shown).
DISCUSSION
We have generated four recombinant viruses in the genetic background of strain AD169 that differ only in the expression of the individual gN genotype. The phenotypes of these viruses in terms of in vitro replication, expression of envelope glycoproteins (gM-gN, gB) and neutralization by gB-and gH-specific mAbs appeared to be similar. However, in neutralization assays using sera from HCMV-infected individuals, we found that some sera neutralized all four strains with comparable efficiency, whereas others showed a clear difference in neutralizing capacity against the individual gN subtype viruses. This finding suggests that the gM-gN complex expresses public epitopes common to all strains of HCMV, as well as strain-specific epitopes that are restricted to single genotypes. The fact that, in our randomly selected serum panel, 30 % of sera showed clear evidence of strain-specific neutralization indicates that it is not an infrequent phenomenon. Moreover, it also suggested that gN constitutes a major determinant for induction of strainspecific neutralizing antibodies, as the strain specificity was detected in the presence of antibodies against additional major antigens such as gB and gH.
It is known that variation in glycosylation pattern of surface antigens can have a profound influence on antibody binding and neutralization. Two extensively studied examples are influenza A virus and human immunodeficiency virus type 1 (HIV-1). The number of carbohydrate-attachment sites on haemagglutinin (HA) of H3 influenza A viruses has increased from three to eight between isolates from 1986 and 2005, respectively (Knossow & Skehel, 2006) . The addition of new oligosaccharides to the globular head of HA provides the virus with an ability to evade antibody pressure (Abe et al., 2004) . During HIV-1 infection, the envelope glycoprotein has been proposed to escape efficient neutralization primarily by changes in N-linked glycosylation. It was postulated that this evolving glycan shield of the exceptionally densely glycosylated envelope protein represents a mechanism to limit antibody recognition and to escape antibody neutralization (Wei et al., 2003) . Positive selection pressure has also been postulated for the evolution of HCMV gN subtypes but, interestingly, the sequence changes in HCMV gN are balanced in terms of O-linked glycosylation sites, such that the loss of a potential O-linked site is balanced by the acquisition of a new site for addition of carbohydrate. In the case of RNA viruses, sequence changes leading to altered glycosylation of envelope proteins can be observed within a relatively short time period, because of the frequency of mutations acquired during genomic replication of these viruses and secondary to immune pressure exerted by the host. Herpesviruses are thought to be genetically more stable than RNA viruses, and sequence variation of conserved genes is a rare event (Stanton et al., 2005) . Thus, mutational events within relevant antigenic sites that are targets for virus-neutralizing antibodies are thought to be infrequent. However, the evolution of genetically stable subtypes within different populations and spread to the naïve population could ultimately result in a similar outcome following exposure to a strain of virus with a polymorphism in virus genes encoding the target of Fig. 4 . Correlation between gN antibody titre (as measured by ELISA) and 50 % neutralization titre. r, Spearman's rank correlation coefficient. Reactivity against: e, gN1; h, gN2; g, gN3; ¾, gN4. gN1  800  1000  1000  1000  gN2  700  600  1100  600  gN3  1500  1500  1600  1500  gN4  800  800  800  1800 protective immune responses. Such an explanation is consistent with findings suggesting that reinfections with HCMV are more common in populations with a higher overall incidence of infection with this virus and presumably, therefore, higher rates of exposure.
The results of our study demonstrated that virus strainspecific neutralization was associated with a higher neutralizing activity against viruses that expressed the gN4 subtype. The molecular basis for this phenomenon is not known at present. However, it is interesting to note that the gM-gN complex of the gN4 subtype virus showed a more diffuse migration pattern in SDS-PAGE than the other gM-gN complexes. Although speculative in the absence of data regarding the glycosylation of the gN subtypes, this result suggested that the sugar modification of gN4 is more heterogeneous than that of the other gN subtypes. This heterogeneity in carbohydrate modifications raises the possibility that a wider spectrum of antibodybinding sites could be accessible on gN4 compared with other gN subtypes, because of either the heterogeneity of occupancy by O-linked sugars or the nature of the carbohydrate itself. Regardless of the explanation, this finding suggested that strain-common antibody-binding sites could be present on gN, but masked by carbohydrates in some gN subtypes. Consistent with this interpretation, findings have been published on the mechanism of antibody recognition of murid herpesvirus 4 (MuHV-4) (Gillet & Stevenson, 2007) . This investigation revealed an additional mechanism by which glycosylation of envelope proteins could contribute to antibody protection/evasion by demonstrating that amino-terminal sequences of MuHV-4 gB, which include O-linked glycans, protect the virus from neutralizing antibodies directed against gH-gL.
In addition to strain-specific neutralization, we also observed strain-independent neutralization. An obvious explanation for this result could be related to the fact that these specific sera do not contain significant titres of gNspecific antibodies and that the neutralization capacity was mediated primarily by antibodies against non-gN glycoproteins, such as gB and/or gH. However, for the sera utilized in this study, this was clearly not the case because gN-specific antibodies were detected. We cannot completely discount the possibility that the strain-independent neutralization activity of a specific serum could be related to the fact that only non-neutralizing antibodies against gN were present and thus neutralization relied on antibodies against the conserved HCMV antigens. However, we view this possibility as unlikely, based on the conservation of antibody reactivity for conserved glycoproteins in most human sera and the presence of multiple gN genotypes in viruses circulating in most populations (Novak et al., 2008) . A more plausible explanation is that these sera contain neutralizing antibodies that react with more than one gN subtype. Such antibodies could originate by at least two different mechanisms. (i) The gN subtypes contain strain-common epitopes. To be consistent with our findings, such an explanation requires that only a fraction of infected hosts will develop antibodies against these public epitopes. There is precedence for this explanation based on an earlier finding that only 50 % of HCMVinfected individuals develop neutralizing antibodies against antigenic domain 2 (AD-2) of gB (Schoppel et al., 1997) . Furthermore, strain-common epitopes are present in gN, based on findings that the murine mAb 14-16A recognized all gN subtypes utilized in the current study.
(ii) The gN subtypes contain only strain-specific epitopes. However, the serum donors were infected with more than one HCMV isolate expressing different gN subtypes, thus producing an antibody repertoire that was capable of neutralizing viruses expressing different gN proteins. This is a likely possibility, as infection with more than one HCMV isolate in different patient populations has been demonstrated in numerous studies (Chandler et al., 1987; Chou, 1989; Meyer-Konig et al., 1998; Coaquette et al., 2004; Novak et al., 2008) . Unfortunately, the gN subtype ELISA could not discriminate between these possibilities. Moreover, non-neutralizing antibodies, which could also be induced against one or more gN subtypes, represent a further complicating factor, as they will bind to transiently expressed gN in an ELISA, but are irrelevant for virus neutralization. Evidence for such a possibility comes from sera such as Ro (Tables 1 and 2 ), which shows a considerable difference in gN-specific ELISA titre, but neutralizes all four viruses equally well.
Thus, the induction and specificity of anti-gN antibodies in the HCMV-neutralizing response are exceedingly complex and preclude a detailed molecular analysis at this time. Most importantly, the number of strains with which a serum donor is infected is impossible to define. We thought that it would be possible to reduce the complexity of the system by immunizing mice with viruses containing a single gN genotype. However, these animals did not produce gN subtype-specific antibodies, although they clearly mounted a gN-specific immune response. This finding is consistent with the broad reactivity of the anti-gN antibody 14-16A used in this study, a mAb generated in mice immunized with a gN1 virus (Britt & Auger, 1985) . Interestingly, using DNA vaccination of rabbits with plasmids encoding gM and gN of strain AD169, Shen et al. (2007) reported the development of gN genotype-independent neutralizing antibodies, indicating that the humoral immune response against gN in rodents after immunization may be different from that of humans following infection with this virus.
An important consideration prompted by this study is the biological consequence of strain-specific neutralization in the biology of HCMV infections. Primary HCMV infection results in production of neutralizing antibodies against multiple envelope glycoproteins ( Mach, 2006) . The respective antibody titres are maintained over long periods of time, presumably because of the persistence of the infecting virus. In combination with cellular immune effector functions, neutralizing antibodies control the infection and limit persistence to a finite number of sites in the organism. In the MCMV model, we have shown that antibodies can protect the infected host even in the absence of cellular immunity (Klenovsek et al., 2007) . In the case of re-exposure to HCMV within the community, which most commonly takes place in form of cell-free virus, virusneutralizing antibodies could provide the first and only line of protection. In this situation, the extent of antigenic dissimilarity between the HCMV isolates could become a critical factor, as a fraction of pre-existing neutralizing antibody will be unable to bind efficiently, or will bind with reduced avidity, to the antigenic determinants on the reinfecting strain. As a consequence, the overall concentration of neutralizing antibody against the reinfecting strain could fall below a critical level for efficient neutralization, and infection can be established. The number of antibodies bound to a virion is a critical factor, as it not only determines the extent of neutralization but, at low occupancy, could also result in enhanced infection of cells bearing IgG Fc receptors (Inada et al., 1985; Ghiasi et al., 2000) . The importance of antibody concentration as a major factor in antiviral protection has been wellestablished in studies of protective antiviral vaccines and in experimental systems that have neutralizing antibody as the only correlate of protection (Zinkernagel & Hengartner, 2006) . In the case of HCMV, results from vaccination trials showed that protection from reinfection is associated with a 10-20-fold higher titre in neutralizing antibodies than was achieved with vaccination in most individuals (Adler et al., 1995) . Such a situation could occur upon exposure to a reinfecting strain of HCMV that exhibits sequence difference in gN, as was determined in our serum panel where the maximum difference in neutralization titre was .8-fold for different gN genotypes.
In infections with MCMV, we have observed that a 2-fold difference in neutralizing-antibody titre has an influence on the course of the infection (A. Bootz, personal communication). It is important to also note that HCMV contains additional envelope proteins such as gO that exhibit extreme polymorphism and that polymorphism between the individual genes appears to be unlinked (Rasmussen et al., 2003) . Moreover, strain-specific epitopes have been identified on gB and gH and strain-specific neutralizing-antibody responses have been observed (Mach, 2006) . These antigens could probably have an additional impact on the strain-specific neutralization of a given serum against heterologous HCMV strains. In the most extreme case, strain specificity could result in a more or less complete neutralization resistance of a reinfecting strain against pre-existing antibodies in a host. That such a situation is not infrequent is indicated by our previous study on strain-specific neutralization, in which we observed that one of nine (11 %) HCMV isolates showed complete resistance to the neutralizing activity of heterologous immune human sera (Klein et al., 1999) . In the case of an immunocompetent host, reinfection of a heterologous HCMV strain will probably occur without clinical symptoms, similar to the course of primary infections in most individuals, and neutralizing antibodies against the reinfecting strain will develop. However, in the case of an immunocompromised host, when the development of a de novo humoral immune response is impaired, reinfection with a different HCMV isolate might result in clinical symptoms, due to unrestricted replication of the 'new' virus strain. Studies from transplant recipients support such mechanisms of disease in these patients (Grundy et al., 1988; Ishibashi et al., 2007) . In addition, in women who are seropositive for HCMV, reinfection with a different strain can result in intrauterine transmission and symptomatic congenital infection (Boppana et al., 2001 ).
In conclusion, our results demonstrate clearly that antigenic variation in a single envelope protein of HCMV is sufficient to escape neutralization by polyspecific antibodies developed during natural infection. This finding adds another facet to the ever-increasing mechanisms that HCMV has developed to evade efficient immune control. The results could have significant implications for the design and development of an HCMV-specific vaccine.
